Journal article

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

Pamela L St Jean, Zhengyu Xue, Nick Carter, Gavin CKW Koh, Stephan Duparc, Maxine Taylor, Claire Beaumont, Alejandro Llanos-Cuentas, Ronnatrai Rueangweerayut, Srivicha Krudsood, Justin A Green, Justin P Rubio

MALARIA JOURNAL | BIOMED CENTRAL LTD | Published : 2016

Abstract

BACKGROUND: Tafenoquine (TQ) and primaquine (PQ) are 8-aminoquinolines (8-AQ) with anti-hypnozoite activity against vivax malaria. PQ is the only FDA-approved medicine for preventing relapsing Plasmodium vivax infection and TQ is currently in phase 3 clinical trials for the same indication. Recent studies have provided evidence that cytochrome P450 (CYP) metabolism via CYP2D6 plays a role in PQ efficacy against P. vivax and have suggested that this effect may extend to other 8-AQs, including TQ. Here, a retrospective pharmacogenetic (PGx) investigation was performed to assess the impact of CYP2D6 metabolism on TQ and PQ efficacy in the treatment of P. vivax in the DETECTIVE study (TAF112582)..

View full abstract